We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Reversal of Alzheimer's Symptoms Achieved Within Minutes

By Biotechdaily staff writers
Posted on 30 Jan 2008
A new study has shown marked improvement in a patient with Alzheimer's disease within minutes of administration of an anti tumor necrosis factor (TNF) therapeutic, a critical component of the brain's immune system.

Researchers at the University of California, Los Angeles (UCLA, USA) hypothesized that elevated levels of TNF-alpha in Alzheimer's disease interfere with the normal regulation of the transmission of neural impulses in the brain. More...
To reduce this elevated TNF, the authors gave a patient with late-onset Alzheimer's disease an injection of an anti-TNF therapeutic called etanercept. The researchers found rapid cognitive improvement, beginning within minutes. While the study only discusses one patient, many other patients with mild to severe Alzheimer's have received the treatment and all have shown sustained and marked improvement. The study was published ahead of print on January 9, 2008, in the online edition of the Journal of Neuroinflammation.

"Rapid cognitive improvement following perispinal etanercept may be related to amelioration of the effects of excess TNF-alpha on synaptic mechanisms in Alzheimer's disease and provides a promising area for additional investigation and therapeutic intervention,” concluded lead author Edward Tobinick M.D., an assistant clinical professor of medicine at UCLA.
.
The study is accompanied by a commentary by Sue Griffin, Ph.D., of the University of Arkansas for Medical Sciences (UAMS, Little Rock, USA), who is also co-editor-in-chief of the Journal of Neuroinflammation.

"It is unprecedented that we can see cognitive and behavioral improvement in a patient with established dementia within minutes of therapeutic intervention,” said Dr. Griffin. "This gives all of us in Alzheimer's research a tremendous new clue about new avenues of research, which is so exciting and so needed in the field of Alzheimer's. Even though this report predominantly discusses a single patient, it is of significant scientific interest because of the potential insight it may give into the processes involved in the brain dysfunction of Alzheimer's.”

TNF-alpha has recently been recognized to be a gliotransmitter that regulates synaptic function in neural networks and also mediates the disruption in synaptic memory mechanisms, which is caused by beta-amyloid and beta-amyloid oligomers.


Related Links:
University of California, Los Angeles

Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Alcohol Testing Device
Dräger Alcotest 7000
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.